BioMarin announces new MPS IVA ERT clinical trial – 4 US sites

BioMarin has slots remaining in their MOR-008 clinical trial for patients with MPS IVA who are not participating in the phase III clinical trial.  There are four sites in the US: NYC, Chicago, Oakland and Houston.  This is a randomized, double-blind, pilot study of the safety and physiological effects of two doses of BMN 110 (enzyme replacement therapy) in patients age 7 or older who are able to walk a minimum of 200 meters.

If you are interested in this clinical trial or have questions about it, please contact Terence Eagleton, MD Senior Medical Director, BioMarin Europe Ltd.,, 415.506.3530.

This entry was posted in News and tagged . Bookmark the permalink.

Comments are closed.